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Background: Thyroid neoplasias with oncocytic features represent a specific phenotype in non-medullary thyroid
cancer, reflecting the unique biological phenomenon of mitochondrial hyperplasia in the cytoplasm. Oncocytic
thyroid cells are characterized by a prominent eosinophilia (or oxyphilia) caused by mitochondrial abundance.
Although disruptive mutations in the mitochondrial DNA (mtDNA) are the most significant hallmark of such tumors,
oncocytomas may be envisioned as heterogeneous neoplasms, characterized by multiple nuclear and mitochondrial
gene lesions. We investigated the nuclear mutational profile of oncocytic tumors to pinpoint the mutations that may
trigger the early oncogenic hit.
Methods: Total DNA was extracted from paraffin-embedded tissues from 45 biopsies of oncocytic tumors.
High-resolution melting was used for mutation screening of mitochondrial complex I subunits genes. Specific
nuclear rearrangements were investigated by RT-PCR (RET/PTC) or on isolated nuclei by interphase FISH (PAX8/PPARγ).
Recurrent point mutations were analyzed by direct sequencing.
Results: In our oncocytic tumor samples, we identified rare TP53 mutations. The series of analyzed cases did not
include poorly- or undifferentiated thyroid carcinomas, and none of the TP53 mutated cases had significant mitotic
activity or high-grade features. Thus, the presence of disruptive TP53 mutations was completely unexpected. In addition,
novel mutations in nuclear-encoded complex I genes were identified.
Conclusions: These findings suggest that nuclear genetic lesions altering the bioenergetics competence of thyroid cells
may give rise to an aberrant mitochondria-centered compensatory mechanism and ultimately to the oncocytic phenotype.
Keywords: Oncocytic carcinoma, Nuclear mitochondrial complex I subunits, Oncogene mutation analysisBackground
Non-medullary thyroid carcinoma (NMTC) is a well-
differentiated thyroid cancer of follicular cell origin, either
papillary thyroid carcinoma (PTC) or follicular thyroid
carcinoma (FTC), which represents the most common
endocrine malignancy. The annual incidence rate* Correspondence: cecilia.evangelisti2@unibo.it; giovanni.tallini@unibo.it
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unless otherwise stated.throughout the world ranges from 0.5 to 10 cases per
100,000 individuals with a two- to four-fold higher inci-
dence of new thyroid cancer cases in women than in men
[1]. The major known environmental risk factor for PTC,
which represents about 80% of all thyroid cancers, is a
prior exposure to radiation, with a dose-dependent effect
on cancer risk. Other risk factors include iodine deficiency
and excess, previous history of benign/autoimmune
thyroid disease, as well as a positive family history [2].
A specific sub-phenotype in NMTC is represented by
thyroid tumors with oncocytic features, which reflects
the unique biological phenomenon of mitochondrialtral. This is an Open Access article distributed under the terms of the Creative
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terized by their prominent eosinophilia (or oxyphilia)
caused by mitochondrial abundance, from where the
histopathological feature of swollen (oncòs) cells origin-
ate. For a thyroid cancer to be diagnosed as oncocytic, at
least 75% of neoplastic cells ought to display the typical
mitochondrial hyperplasia according to the 2004 World
Health Organization classification [3].
Thyroid oncocytic tumors (with the exception of the
rare oncocytic variant of medullary carcinoma) originate
from follicular cells. They can be benign (oncocytic
adenomas) or malignant (oncocytic carcinomas). It is
generally accepted that oncocytic tumors in the thyroid
and in other organs alike should be considered as distinct
subtypes, since their features are peculiar enough to set
them apart from corresponding neoplasms lacking accu-
mulation of mitochondria (World Health Organization,
2004). Accordingly, oncocytic thyroid carcinomas are now
classified as variants of follicular carcinoma (commonly)
or of papillary carcinoma (less commonly). Interestingly,
oncocytic carcinoma (OC) have long been considered a
more aggressive subtype than PTC or FTC, particularly
since they often appear to be refractory to radioactive
iodine treatment and have poor chemo-sensitivity [4].
Overall, canonical histopathological criteria such as
invasion of the tumor capsule or blood vessels are
considered in order to distinguish benign versus
malignant forms, regardless of the occurrence of an
oncocytic phenotype. Among the molecular hallmarks
of this phenotype, it has to be underlined that, in keep-
ing with the observation that most of the time oncocytic
cells mitochondria display a deranged morphology and
function [5], disruptive mutations in the mitochondrial
DNA (mtDNA) are nowadays univocally considered
as the most prominent and frequent genetic signature
for oncocytic tumors of the thyroid and other organs
as well [6].
We and other groups have thereby demonstrated that
pathogenic mutations in mtDNA encoded-genes impair-
ing complex I are genetic markers of thyroid oncocytic
tumors [7-9], albeit it has to be noted that in other or-
gans, such as kidney and pituitary gland, the correlation
between the occurrence of such mutations, the oncocytic
phenotype and the functional disruption of complex
I activity is far more stringent than in the thyroid
[6,10-13]. Thyroid tumors may present as heterogeneous
neoplasms, in which oncocytic cells are more or less a
predominant component, and heterogeneity of nuclear
and mitochondrial gene lesions may be envisioned
[5,14]. Overall, since oncocytic features are present both
in PTC and FTC and a number of oncocytic thyroid
cancers are devoid of mtDNA disruptive mutations [7],
the nuclear profile of oncocytic thyroid tumors is worth
investigating, in order to pinpoint the mutations thatmay trigger the first hit in thyroid oncogenesis and may
help in distinguishing, together with histological and
cytological data, oncocytic tumors subtypes.
In forty-five oncocytic tumors of known mitochondrial
DNA mutation status we therefore performed a screening
survey of the nuclear encoded subunits of mitochondrial
complex I, and of genes typically altered in thyroid-specific
tumors such as B-Raf proto-oncogene (BRAF), Harvey
rat sarcoma viral oncogene homolog (H-RAS), Neuro-
blastoma RAS viral oncogene homolog (N-RAS), and
Kirsten rat sarcoma viral oncogene homolog (K-RAS),
the fusion genes REarranged during Transfection (RET)/
PTC1, RET/PTC3, Paired Box 8 (PAX8)/peroxisome
proliferator-activated receptor gamma (PPARγ), and
Tumor Protein p53 (TP53).
Methods
Tissue samples features
Forty-five tumor tissues samples were obtained from the
Department of Experimental, Diagnostic and Specialty
Medicine (DIMES), University of Bologna. Clinical and
histological characterization was performed as pre-
viously described [7]. Briefly, 16 were hyperplastic
oncocytic thyroid nodules, 7 were thyroid follicular
adenomas (FA) and 22 were oncocytic thyroid carcin-
omas. Average patient age was 53 for patients with
oncocytic lesions. All tumors were sporadic. The study
was approved by the Ethical Committee of Azienda
Ospedaliero-Universitaria of Bologna, protocol number
26/2009/U/Tess and handling of samples and clinical
data proceeded accordingly. Patients’ description is re-
ported in Additional file 1: Table S1. Written informed
consent was obtained for each patient included in
the study and all data from the patients were handled
in accordance with the local ethical committee ap-
proved protocols and in compliance with the Helsinki
declaration.
Screening of TP53, BRAF, H-RAS, K-RAS and N-RAS genes
All thyroid oncocytic samples were screened for TP53
mutations by polymerase chain reaction (PCR) and dir-
ect sequencing, as reported before [15]. PCR products
were purified onto Millipore PCR clean-up plates, resus-
pended in bi-distilled water, and directly sequenced on
both strands using BigDye v1.1 (Life Technologies) ac-
cording to manufacturer’s instructions. Samples were
loaded on an ABI3730 automated sequencing machines
(Life Technologies) and analyzed using Sequencer v2.1.
Detection of BRAF p.600 V > E and RAS codon 61
mutations was performed using PCR primers as re-
ported in [16], sequenced using a CEQ2000 Genetic
Analysis Systems (Beckman Coulter, Fullerton, CA, USA)
and analyzed using CEQanalyzer software (Beckman
Coulter, Fullerton, CA, USA) as previously described [16].
Figure 1 PAX8/PPARγ rearrangement observed in isolated nuclei
from an oncocytic tumor biopsy. The white arrow indicates the
gene fusion observed with the two differently labeled probes. See
text for details.
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Total RNA was extracted using the RecoverAll kit
(Ambion Inc., Austin, Texas, USA) starting from four
20-μm-thick slides, in accordance to the manufacturer’s
instructions. RNA concentration was measured using
Quant-itTM RNA kit (Invitrogen, Carlsbad, California).
Reverse-transcription PCR was performed using the
Transcriptor High Fidelity cDNA Synthesis Sample Kit
(Roche Diagnostic, Mannheim, Germany) and cDNA
amplified using the FastStartTaq DNA polymerase re-
agents (Roche Applied Science, Mannheim, Germany),
starting from about 100 ng of extracted RNA. RET re-
arrangement was analyzed by real time RT-PCR using
primers specific for c-RET exons 10–11, c-RET exons
12–13, RET/PTC1 and RET/PTC3 as previously de-
scribed [17]. Real time RT-PCR reactions were run in
duplicate. The beta-Actin reference gene was used as
RNA control. Real-time PCR was performed using an
ABI SDS 7000™ instrument (Applied Biosystems, Foster
City, CA, USA).
PAX8/PPARγ analysis
To identify the PAX8/PPARγ rearrangement, a dual-
color single-fusion home-brew probe containing BACs
RP11-339 F22 (for PAX8) labeled with Spectrum Orange
(Abbott Molecular/Vysis Downers Grove, IL) and RP11-
167 M22 (for PPARγ) labeled with Spectrum Green
(Abbott Molecular/Vysis) was designed. Cytogenetic and
fluorescence in situ hybridization (FISH) studies were
performed as described [18]. Evaluation of the results
was done by counting 25–105 nuclei (mean 65) per case,
depending on the quality of preparations, using a digital
image analysis system based on an epifluorescence
Olympus BX41 microscope and charge-coupled device
camera (Cohu), interfaced with the CytoVysion system
(software 2.81 Applied Imaging, Pittsburg, PA, USA).
Normal nuclei were identified by two orange and two
green FISH signals, nuclei with PAX8/PPARγ gene
fusion were identified by one orange, one green and one
fused orange/green signal. An example of the observed
nuclear pattern is reported in Figure 1.
Mutation screening of nuclear mitochondrial complex I
subunits
Total DNA was extracted from tissues by the use of
NucleoSpin Tissue extraction kit (Machery-Nagel) accord-
ing to the manufacturer’s instructions. All DNAs were
pre-amplified using the GenomiPhi Illustra v2.0 ampli-
fication kit starting from 10 ng genomic DNA from tumor
tissues according to the manufacturer’s instructions
(GE Healthcare, UK). A screening analysis for muta-
tions in the nuclear subunits of mitochondrial complex
I and assembly factors for complex I was carried out by
high resolution melting point analysis (HRMA, IdahoTechnology, USA) of PCR products of the coding and
flanking intronic regions of these genes from pre-
amplified DNA as described [19,20].
All PCR products presenting an aberrant melting pro-
file were re-amplified from the corresponding original
genomic DNA with the same PCR primers included in the
screening. Sequence analysis (ABI3730, Life Technologies)
was performed according to the manufacturer. PCR
primer sequences and conditions were performed as
reported [19,20].
Results
Nuclear mitochondrial complex I mutation screening
The DNA extracted from 45 sporadic thyroid oncocytic
tumors was screened for mutations in the 38 nuclear
genes encoding the subunits of mitochondrial complex I
and two known complex I assembly factors (ECSIT;
C6orf66). For all tumor samples the mtDNA mutation
status has been previously determined [7]. We identified
four heterozygous changes in four complex I genes. Two
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bases: the missense change p. 81Arg > Gln in NDUFB1
(NM_004545.3, c.242G > A, rs72691104), with a very
low frequency in control population (A = 1, G = 8599;
m.a.f. = 0.0116, http://evs.gs.washington.edu/EVS/) and
a common silent change in NDUFC2, corresponding to
dbSNP ID rs534418 (m.a.f = 0.8546). Furthermore, an
in-frame deletion of one amino acid residue was identi-
fied, c.398_400del3 p.(K133_I134delinsI) in NDUFA12,
which despite having no dbSNP entry, was found in the
control population at a low frequency (Table 1). More-
over, a novel variant was detected, namely the missense
change p.8Glu > Val in NDUFB6, in an oncocytic carcin-
oma. The change was absent from 400 control chromo-
somes (blood-derived DNA) and from public databases
(1000 Genomes and NIH-Exome Variant Server). In
silico prediction of the putative functional effect was
carried out with the programs PolyPhen-2, Provean and
SIFT, all of which indicated as damaging the variant
p.8Glu > Val in NDUFB6, whereas conflicting results
arose for the p. 81Arg > Gln in NDUFB12 (Table 1 and
Additional file 1: Table S2). This sample also carried the
mtDNA m.11403G > A, inserting a premature stop-
codon in ND4 (p.W215Ter, Additional file 1: Table S1).
The NDUFB6 affecting p.8 Glu residue maps to the
mitochondrial targeting sequence (MTS) of the protein, in
a position highly conserved throughout species (Additional
file 2: Figure S1A); therefore, it is reasonable to hypothesize
that such a non-conservative change may be highly
deleterious for the correct mitochondrial localization of
the protein. In addition, this change resulted to be
tumor-specific (Additional file 2: Figure S1B). The one-
amino acid deletion in NDUFA12 was instead present
also in the non-cancer tissue surrounding the lesion.
This case also carried the PAX8/PPARγ rearrangement
(see below).
Evaluation of mutations in BRAF and RAS, and RET/PTC1-3
and PAX8-PPARγ rearrangements
The BRAFV600E mutation was found in 2/45 samples (4.4%);
RAS genes (H-RAS, K-RAS and N-RAS) were collectively
mutated in 3/45 samples (6.7%). The RET/PTC1 rearrange-
ment was analyzed in 26 cases and it was found in 1 out of
26 (3.8%). Results are presented in Table 2.
Considering the high frequency of mtDNA mutations
in these samples and the role of PPARγ in mitochondrialTable 1 Coding variants identified in nuclear mitochondrial c
Gene Position in cDNA Number of h
oncocytic Thy
NDUFA12 c. 398–400 del_AGA (NM_018838.4) 1/45
NDUFB1rs72691104 c. 242G > A (NM_004545.3) 1/45
NDUFB6 c. 125A > T (NM_002493.4) 1/45
aEVS (http://evs.gs.washington.edu/EVS/) accession as by June, 26th 2014.biogenesis [21,22], we next hypothesized that PPARγ
rearrangement might be preferentially associated with
occurrence of mtDNA mutations. As a pilot study,
PAX8-PPARγ rearrangements were analyzed in 10 sam-
ples, previously characterized for mtDNA mutations, in
order to investigate whether this event is an alternative
or concurrent mutational hit with mtDNA mutations in
oncocytic thyroid lesions. The PAX8-PPARγ rearrange-
ment was found in 5 out of 10 cases (mean fusion:
12.46%). Three samples carried concurrently the re-
arrangement and mtDNA mutations, and three samples
negative for the rearrangement carried mtDNA mutations
(Additional file 1: Table S1). These findings suggest the
lack of a stringent association between PAX8-PPARγ and
mtDNA mutations.
TP53 mutation screening
All 45 tumor samples were screened for TP53 muta-
tions: we identified two frameshift deletions and one
missense change in 3 cases (6.7%; Table 3). All changes
were detected as heterozygous variants. The missense
change p.364 Ala > Thr was present in a sample from an
oncocytic carcinoma, carrying also a frameshift mutation in
mtDNA-encoded ND4 subunit (m.11038delA). The TP53
missense change was not present in databases of controls
(i.e. ESP), but it has been reported in COSMIC as somatic
mutation in ovarian cancer (accession n: COSM46361).
Different prediction programs gave discrepant results on its
pathogenicity (Additional file 1: Table S2).
One heterozygous deletion at c.728 was present in a
sample from an oncocytic carcinoma, carrying the
m.10885del, inserting a stop codon at amino acid 61 in
mtDNA-encoded subunit ND4. The frameshift c.1248del
was present in one sample, from an oncocytic adenoma,
carrying also the N-RAS mutation. None of the TP53
mutated cases had poorly- or undifferentiated histologic
features.
The (co)occurrence of all genetic lesions identified is
reported in Additional file 1: Table S1.
Discussion
Previous work carried out by our group has shed light
on the tight correlation between the co-occurrence of
mtDNA alterations, the oncocytic phenotype, and a heavy
dysfunction in the oxidative phosphorylation (OXPHOS)





Type of change PolyPhen-2 score
(HumVar)
21/6259 p.133del (Lys_Ile134insIle) —
1/4300 p.Arg81Gln 0.890
— p.Glu8Val 0.852
Table 2 Oncogenes altered in oncocytic thyroid tumors
Oncogene Type of mutation Type of change Number of oncogenic eventsa
RET/PTC rearrangement RET/PTC1 1/26
PAX8-PPARγ rearrangement — 5/10
RAS (H-RAS, K-RAS, and N-RAS) point mutation p.61 Gln > Arg (Q61R H-, N-, and K-RAS) 3/45
BRAF point mutation p.600Val > Glu (V600E) 2/45
aTotal numbers of tested samples are different, since the different analyses were not possible in all tissues.
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functional impairment of complex I is even more striking
in other oncocytomas, e.g. renal and pituitary oncocytic
tumors [11-14].
Oncocytic thyroid tumors of follicular cell derivation
are classified by the World Health Organization 2004 as
distinctive histologic variants of FTC and PTC. This
would suggest that they carry genetic abnormalities similar
to those of their corresponding non-oncocytic counter-
parts (FTC and PTC) [23].
In comparison with other tumor types comprehensive
molecular analyses of oncoytic thyroid tumors, including
comparative genomic hybridization studies, have not
been widely reported [24]. Recent work on oncocytic
thyroid carcinomas found a series of recurrent deletion/
amplification in different chromosomes [25], confirming
previously reported associations with chromosome in-
stability [26]. This level of chromosome instability is
remarkable when compared with that of other types of
non-oncocytic differentiated thyroid cancer. BRAF muta-
tions, RET/PTC or PAX8-PPARγ rearrangements were
not identified [25]. RAS mutations were found in onco-
cytic FTCs with a much lower prevalence compared to
the one of the corresponding non-oncocytic FTCs [25].
The finding of chromosome instability in oncocytic
thyroid carcinoma may contribute to explain the pecu-
liar phenotype of the tumors, i.e. the aberrant mitochon-
drial hyperplasia that, in a relatively high percentage of
cases, is tightly associated to the occurrence of clearly
pathogenic mitochondrial DNA mutations.
A complete analysis of the genomic landscape of onco-
cytic thyroid tumors, correlated with the co-occurrence
of mtDNA mutations and in other complex I nuclear-
encoded genes, has not been reported so far. Therefore,
we performed an extensive mutation analysis of oncocytic
tumor biopsies, previously characterized for the presence
of mtDNA mutations. The presence of the best-knownTable 3 Mutations in TP53 tumor suppressor gene
Base change
(NM_000546)
Amino acid change Number of
het samples
c. 728delC frameshift 1/45
c. 1248delC frameshift 1/45
c. 1341G > A missense change
(p.364Ala > Thr)
1/45oncogenic events in thyroid cancer, including BRAF, RAS,
TP53 mutations, RET/PTC and PAX8/PPARγ rearran-
gements, was assessed in addition to a high-throughput
mutation screening for the nuclear-encoded complex I
subunits [27], which may account for those cases lacking
mtDNA mutations. The resulting data show that, in our
samples, the BRAF, RAS, RET/PTC oncogenic events are
relatively rare, similar to what observed by Ganly et al.
[25]. On the other hand, the PAX8/PPARγ rearrangement
did not show any significant correlation with the presence
of mtDNA mutations, although the analysis was per-
formed as a pilot study on a small number cases, which
may also explain the relatively high frequency of PAX8/
PPARγ rearrangement with respect to previously pub-
lished data.
Our study shows that heterozygous TP53 disruptive
mutations are present in a small subset of oncocytic
tumors. Two cases were oncocytic follicular carcinomas
and one was diagnosed as oncocytic follicular adenoma.
TP53 mutations are typically associated with poorly
differentiated and anaplastic thyroid carcinoma [28]. The
series of cases that we analyzed did not include poorly-
or undifferentiated thyroid carcinomas, and none of our
TP53 mutated cases had significant mitotic activity or
high-grade features. Thus, the presence of disruptive
TP53 mutations, albeit in a subset of cases, was com-
pletely unexpected. Interestingly, TP53 mutations have
been recently reported in 4 of 18 oncocytic carcinomas
using Targeted Next-Generation Sequencing [29].
The occurrence of TP53 mutations in oncocytic tumors
that do not carry the features of poorly-differentiated or
anaplastic thyroid cancers is intriguing. Two of our TP53
mutated samples also harboured mtDNA mutations.
Tumor suppressor p53 has been largely implicated in
the metabolic remodeling that cancer cells develop
during progression, particularly through the regulation
of mitochondrial respiration via TIGAR and COXIV of
the respiratory chain [30]. Nevertheless, several studies
have shown that in thyroid oncocytic tumors a burden
of mtDNA mutations all impinging on the bioenergetics
competence of thyroid cells may give rise to an aberrant
mitochondria-centered compensatory mechanisms and
ultimately to the oncocytic phenotype [14].
In contrast to the findings that disruptive mtDNA
mutations, in particular in genes encoding complex I
Evangelisti et al. BMC Cancer  (2015) 15:157 Page 6 of 7subunits, are fairly common in oncocytic tumors, we did
not identify a large number of nuclear-encoded complex I
genetic abnormalities, suggesting that mutations in these
genes do not play a major role in oncocytic thyroid cancer.
This indicates that other genomic alterations may induce
metabolic microenvironment changes drivers of tumori-
genesis, coupled to mitochondrial abnormalities [13,31].Conclusions
Characterizing the genomic landscape both at nuclear
and mitochondrial levels in oncocytic thyroid tumors
reveals a complex genetic interplay that may also confer
prognostic differences. Available massive sequencing tech-
nologies, leading to the simultaneous analysis of hundreds
of different genetic regions, are increasing the molecular
characterization of solid tumors. Based on our data that
show the co-occurrence of multiple genetic damages, a
similar approach is indicated also for the characterization
of oncocytic thyroid tumors, in order to identify the best
therapeutic targets for a personalized treatment of thyroid
cancer subtypes.Additional files
Additional file 1: Table S1. Clinical characteristics and molecular
defects nuclear genes and mtDNA alterations. Table S2. PROVEAN and
SIFT output for the rare variants identified in oncocytic tumors.
Additional file 2: Figure S1. (A) Protein sequence alignment showing
the conservation across species of NDUFB6 p.8 Glu. (B) Electropherograms
showing the novel missense change in NDFUB6 p.8 Glu > Val. Tumor tissue
sample showing a somatic heterozygous profile, compared to perilesional
tissue. The two different alleles were distinguished by cloning the PCR
products into pcDNAII vector and sequencing the different clones.
Abbreviations
NMTC: Non-medullary thyroid carcinoma; PTC: Papillary thyroid carcinoma;
FTC: Follicular thyroid carcinoma; OC: Oncocytic carcinoma;
mtDNA: Mitochondrial DNA (mtDNA); FA: Follicular adenoma.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EB, GG, GT conceived and designed the experiments. CE, IK, DdB, CC, PC, RV
performed the experiments. TM and HP were in charge of high resolution
melting analysis and interpretation. GT and GR recruited patients and provided
data interpretation and manuscript organization. CE, EB, GG wrote the paper. All
authors read and approved the final manuscript.
Authors’ information
Cecilia Evangelisti and Dario de Biase share first authorship.
Acknowledgements
We thank Ms. D. Rosano and Ms. D.V. Frau for technical help. This work was
supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) grants
“TRANSMIT” (IG8810) to G.R. and “JANEUTICS” (IG14242) to G.G., by grant
GRERGENE “DIANE” from the Regione Emilia-Romagna-Italian Ministry of
Health to E.B. and by an Italian Government MIUR grant (20074ZW8LA) to G.
T.; I.K. is supported by a triennial “Borromeo” AIRC fellowship.Author details
1Department of Medical and Surgical Sciences (DIMEC), Policlinico S.
Orsola-Malpighi, Unit of Medical Genetics, University of Bologna, Bologna, Italy.
2Department of Biomedical and Neuromotor Sciences (DIBINEM), Cell Signaling
Laboratory, University of Bologna, Bologna, Italy. 3Department of Diagnostic,
Experimental and Specialty Medicine (DIMES), Unit of Anatomic Pathology,
Bellaria Hospital, University of Bologna, Bologna, Italy. 4Department of
Diagnostic, Experimental and Specialty Medicine (DIMES), Unit of Anatomy,
Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy. 5Helmholtz
Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt,
Neuherberg, Germany. 6Department of Biomedical Sciences, University of
Cagliari, Cagliari, Italy.
Received: 22 September 2014 Accepted: 24 February 2015References
1. Bonora E, Tallini G, Romeo G. Genetic predisposition to familial nonmedullary
thyroid cancer: an update of molecular findings and state-of-the-Art studies.
J Oncol. 2010;2010:385206.
2. Alsanea O, Clark OH. Familial thyroid cancer. Curr Opin Oncol. 2001;13(1):44–51.
3. Tallini G. Oncocytic tumours. Virchows Arch. 1998;433(1):5–12.
4. Gasparre G, Bonora E, Tallini G, Romeo G. Molecular features of thyroid
oncocytic tumors. Mol Cell Endocrinol. 2010;321(1):67–76.
5. Maximo V, Rios E, Sobrinho-Simoes M. Oncocytic lesions of the thyroid,
kidney, salivary glands, adrenal cortex, and parathyroid glands. Int J Surg
Pathol. 2014;22(1):33–6.
6. Gasparre G, Romeo G, Rugolo M, Porcelli AM. Learning from oncocytic
tumors: why choose inefficient mitochondria? Biochim Biophys Acta.
2011;1807(6):633–42.
7. Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, et al.
Disruptive mitochondrial DNA mutations in complex I subunits are markers
of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A.
2007;104(21):9001–6.
8. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M.
Mitochondrial DNA somatic mutations (point mutations and large deletions)
and mitochondrial DNA variants in human thyroid pathology: a study with
emphasis on Hurthle cell tumors. Am J Pathol. 2002;160(5):1857–65.
9. Pereira L, Soares P, Maximo V, Samuels DC. Somatic mitochondrial DNA
mutations in cancer escape purifying selection and high pathogenicity
mutations lead to the oncocytic phenotype: pathogenicity analysis of
reported somatic mtDNA mutations in tumors. BMC Cancer. 2012;12:53.
10. Gasparre G, Porcelli AM, Lenaz G, Romeo G. Relevance of mitochondrial
genetics and metabolism in cancer development. Cold Spring Harb Perspect
Biol. 2013;5:2. doi: 10.1101/cshperspect.a011411.
11. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kogler C, Ratschek M,
et al. Loss of complex I due to mitochondrial DNA mutations in renal
oncocytoma. Clin Cancer Res. 2008;14(8):2270–5.
12. Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M,
et al. Clonal expansion of mutated mitochondrial DNA is associated with
tumor formation and complex I deficiency in the benign renal oncocytoma.
Hum Mol Genet. 2008;17(7):986–95.
13. Kurelac I, MacKay A, Lambros MB, Di Cesare E, Cenacchi G, Ceccarelli C, et al.
Somatic complex I disruptive mitochondrial DNA mutations are modifiers of
tumorigenesis that correlate with low genomic instability in pituitary adenomas.
Hum Mol Genet. 2013;22(2):226–38.
14. Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, et al. The
genetic and metabolic signature of oncocytic transformation implicates
HIF1alpha destabilization. Hum Mol Genet. 2010;19(6):1019–32.
15. Bartoletti-Stella A, Mariani E, Kurelac I, Maresca A, Caratozzolo MF, Iommarini
L, et al. Gamma rays induce a p53-independent mitochondrial biogenesis
that is counter-regulated by HIF1alpha. Cell Death Dis. 2013;4:e663.
16. Piana S, Ragazzi M, Tallini G, de Biase D, Ciarrocchi A, Frasoldati A, et al.
Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor
progression in lymph node metastases: report of 3 cases, with morphological
and molecular analysis. Hum Pathol. 2013;44(4):556–65.
17. Rhoden KJ, Johnson C, Brandao G, Howe JG, Smith BR, Tallini G. Real-time
quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3
expression patterns in papillary thyroid carcinoma. Lab Invest.
2004;84(12):1557–70.
Evangelisti et al. BMC Cancer  (2015) 15:157 Page 7 of 718. Caria P, Dettori T, Frau DV, Di Oto E, Morandi L, Parmeggiani A, et al.
Simultaneous occurrence of PAX8-PPARg and RET-PTC3 rearrangements in
a follicular variant of papillary thyroid carcinoma. Am J Surg Pathol.
2012;36(9):1415–20.
19. Haack TB, Madignier F, Herzer M, Lamantea E, Danhauser K, Invernizzi F,
et al. Mutation screening of 75 candidate genes in 152 complex I deficiency
cases identifies pathogenic variants in 16 genes including NDUFB9. J Med
Genet. 2012;49(2):83–9.
20. Haack TB, Gorza M, Danhauser K, Mayr JA, Haberberger B, Wieland T, et al.
Phenotypic spectrum of eleven patients and five novel MTFMT mutations
identified by exome sequencing and candidate gene screening. Mol Genet
Metab. 2014;111(3):342–52.
21. Skildum A, Dornfeld K, Wallace K. Mitochondrial amplification selectively
increases doxorubicin sensitivity in breast cancer cells with acquired
antiestrogen resistance. Breast Cancer Res Treat. 2011;129(3):785–97.
22. Corona JC, de Souza SC, Duchen MR. PPARgamma activation rescues
mitochondrial function from inhibition of complex I and loss of PINK1.
Exp Neurol. 2014;253:16–27.
23. Salvadori B, Greco M, Clemente C, De Lellis R, Delledonne V, Galluzzo D, et al.
Prognostic factors in operable breast cancer. Tumori. 1983;69(5):477–84.
24. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al.
The landscape of cancer genes and mutational processes in breast cancer.
Nature. 2012;486(7403):400–4.
25. Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. Genomic
dissection of Hurthle cell carcinoma reveals a unique class of thyroid
malignancy. J Clin Endocrinol Metab. 2013;98(5):E962–72.
26. Dettori T, Frau DV, Lai ML, Mariotti S, Uccheddu A, Daniele GM, et al.
Aneuploidy in oncocytic lesions of the thyroid gland: diffuse accumulation
of mitochondria within the cell is associated with trisomy 7 and progressive
numerical chromosomal alterations. Genes Chromosomes Cancer.
2003;38(1):22–31.
27. Ugalde C, Janssen RJ, van den Heuvel LP, Smeitink JA, Nijtmans LG.
Differences in assembly or stability of complex I and other mitochondrial
OXPHOS complexes in inherited complex I deficiency. Hum Mol Genet.
2004;13(6):659–67.
28. Romitti M, Ceolin L, Siqueira DR, Ferreira CV, Wajner SM, Maia AL. Signaling
pathways in follicular cell-derived thyroid carcinomas (review). Int J Oncol.
2013;42(1):19–28.
29. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation
sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.
J Clin Endocrinol Metab. 2013;98(11):E1852–60.
30. Gerin I, Noel G, Bolsee J, Haumont O, Van Schaftingen E, Bommer GT.
Identification of TP53-induced glycolysis and apoptosis regulator (TIGAR) as
the phosphoglycolate-independent 2,3-bisphosphoglycerate phosphatase.
Biochem J. 2014;458(3):439–48.
31. Iommarini L, Kurelac I, Capristo M, Calvaruso MA, Giorgio V, Bergamini C,
et al. Different mtDNA mutations modify tumor progression in dependence
of the degree of respiratory complex I impairment. Hum Mol Genet.
2014;23(6):1453–66.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
